Positive effect of septimeb™ on mortality rate in severe sepsis: A novel non antibiotic strategy

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Eslami, Kaveh ^a,b   Mahmoodpoor, Ata ^c   Ahmadi, Arezoo ^a   Abdollahi, Mohammad ^a   Kamali, Koorosh ^d   Mousavi, Sarah ^e   Najafi, Atabak ^a   Baeeri, Maryam ^a   Hamishehkar, Hadi ^f   Kouti, Leila ^b   Javadi, Mohammadreza ^a   Mojtahedzadeh, Mojtaba ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ICU; Immunomodulation; Septimeb; Severe sepsis

Indexed keywords

GELATINASE A; IMMUNOMODULATING AGENT; INTERLEUKIN 2; PLATELET DERIVED GROWTH FACTOR; SEPTIMEB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BLOOD SAMPLING; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HERBAL MEDICINE; HUMAN; MALE; MORTALITY; MULTICENTER STUDY; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SCORING SYSTEM; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SINGLE BLIND PROCEDURE;

EID: 84870398949     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-40     Document Type: Article

References (45)

1. Sepsis mortality prediction based on predisposition, infection and response. Moreno RP, Metnitz B, Adler L, Hoechtl A, Bauer P, Metnitz PGH, Intensive Care Med 2008 34 496 504 10.1007/s00134-007-0943-1 18060541 (Pubitemid 351623030)
2. Severe sepsis and septic shock: a prospective population-based study in Icelandic intensive care units. Vesteinsdottir E, Karason S, Sigurdsson SE, Gottfredsson M, Sigurdsson GH, Acta Anaesthesiol Scand 2011 55 722 731 10.1111/j.1399-6576.2011.02437.x 21480832
3. [Physiopathology of severe sepsis]. Caille V, Bossi P, Grimaldi D, Vieillard-Baro A, Presse Med 2004 33 256 261 discussion 269 10.1016/S0755- 4982(04)98551-X 15029017
4. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT, Critical Care 2007 11 49 10.1186/cc5783 17448250 (Pubitemid 46805280)
5. Place of iron chelators like desferrioxamine and deferasirox in management of hyperoxia-induced lung injury: A systematic review. Mousavi S, Mojtahedzadeh M, Abdollahi M, Int J Pharmacol 2010 6 326 337
6. Recombinant human erythropoietin reduces plasminogen activator inhibitor and ameliorates pro-inflammatory responses following trauma. Shiehmorteza M, Ahmadi A, Abdollahi M, Nayebpour M, Mohammadi M, Hamishehkar H, Najafi A, Pazoki M, Mojtahedzadeh M, DARU J Pharmaceut Sci 2011 19 159 165
7. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, Khajavi MR, Rouini MR, Moradi M, Mohammadirad A, Abdollahi M, Hum Exp Toxicol 2007 26 697 703 10.1177/0960327107083452 17984140 (Pubitemid 350157338)
8. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. Gogos CA, Drosou E, Bassaris HP, Skoutelis A, J Infect Dis 2000 181 176 180 10.1086/315214 10608764 (Pubitemid 30049046)
9. Plasma pro-and anti-inflammatory cytokine levels and outcome prediction in unselected critically ill patients. Dimopoulou I, Orfanos S, Kotanidou A, Livaditi O, Giamarellos-Bourboulis E, Athanasiou C, Korovesi I, Sotiropoulou C, Kopterides P, Ilias I, Cytokine 2008 41 263 267 10.1016/j.cyto.2007.11.019 18191577
10. Identification of enhanced cytokine generation following sepsis. Dream of magic bullet for mortality prediction and therapeutic evaluation. Hamishehkar HB MT, Abdollahi M, Ahmadi A, Ahmadi A, Mahmoodpour, Mirjalili MR, Abrishami R, Khoshayand MR, Eslami K, Kanani M, Baeeri M, Mojtahedzadeh M, DARU 2010 18 155 162 22615611
11. Corticosteroid therapy in patients with severe sepsis and septic shock. Keh D, Goodman S, Sprung CL, Semin Respir Crit Care Med 2004 25 713 719 10.1055/s-2004-860985 16088513 (Pubitemid 40041591)
12. Corticosteroid therapy for severe sepsis and septic shock. Minneci PC, Deans KJ, Natanson C, JAMA 2009 302 1643 author reply 1644-1645 19843895
13. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, et al. Crit Care Med 2004 32 2173 2182 15640628 (Pubitemid 39491795)
14. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, et al. Crit Care Med 2001 29 765 769 10.1097/00003246-200104000-00015 11373466 (Pubitemid 32299714)
15. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Knaus WA, Harrell FE Jr, LaBrecque JF, Wagner DP, Pribble JP, Draper EA, Fisher CJ Jr, Soll L, Crit Care Med 1996 24 46 56 10.1097/00003246-199601000- 00010 8565538 (Pubitemid 26151595)
16. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C, Simpson JA, Leelarasamee A, Curtis L, White NJ, Antimicrob Agents Chemother 2000 44 693 696 10.1128/AAC.44.3.693-696.2000 10681340 (Pubitemid 30117963)
17. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Vincent JL, Spapen H, Bakker J, Webster NR, Curtis L, Crit Care Med 2000 28 638 642 10.1097/00003246-200003000-00006 10752807 (Pubitemid 30174255)
18. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, et al. Crit Care Med 2007 35 118 126 10.1097/01.CCM. 0000251124.83436.0E 17095947 (Pubitemid 46035686)
19. High-dose selenium substitution in sepsis: a prospective randomized clinical trial. Valenta J, Brodska H, Drabek T, Hendl J, Kazda A, Intensive Care Med 2011 37 808 815 10.1007/s00134-011-2153-0 21347869
20. Comparison the inflammatory effects of early supplemental parenteral nutrition plus enteral nutrition versus enteral nutrition alone in critically ill patients. Abrishami RA A, Abdollahi M, Moosivand A, Khalili H, Najafi A, Gholami K, Hamishehkar H, Yazdi AP, Mojtahedzadeh M, daru 2010 18 103 106 22615602
21. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Bernard GR, Crit Care Med 2003 31 85 93 10.1097/00003246-200301001-00012 12544981
22. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Hack CE, Ogilvie AC, Eisele B, Jansen PM, Wagstaff J, Thijs LG, Prog Clin Biol Res 1994 388 335 357 7831367
23. Evaluation of the effects of pulse high-volume hemofiltration in patients with severe sepsis: a preliminary study. Peng Z, Pai P, Han-Min W, Jun Z, Hong-Bao L, Rong L, Chen H, Int J Artif Organs 2010 33 505 511 20872345
24. Botanical immunodrugs: scope and opportunities. Patwardhan B, Gautam M, Drug Discov Today 2005 10 495 502 10.1016/S1359-6446(04)03357-4 15809195 (Pubitemid 40487492)
25. Safety and Efficacy of Setarud (IMOD (TM)) Among People Living with HIV/AIDS. A Review. Paydary K, Emamzadeh-Fard S, Khorshid H, Kamali K, Seyed AS, Mohraz M, Recent patents on anti-infective drug discovery 2012 7 66 72 10.2174/157489112799829756 22353002
26. etarud (IMODTM) as a multiherbal drug with promising benefits in animal and human studies: A comprehensive review of biochemical and cellular evidences. Mohammadirad AK-KH, Gharibdoost F, Abdollahi M, Asian J Anim Vet Adv 2011 6 1185 1192 10.3923/ajava.2011.1185.1192
27. Evaluation of safety and efficacy of IMOD inb patients with HIV/AIDS. Mohraz M, S B, F M, K K, c R, Iranian J Allergy Asthma Immunol 2007 6 10
28. A clinical trial on the efficacy of IMOD in AIDS patients. Mohraz M, Khairandish P, Kazerooni PA, Davarpanah MA, Shahhosseiny MH, Mahdavian B, Vaziry S, Shahriary S, Kamali K, Khorshid KHR, et al. Daru-J Pharmaceut Sci 2009 17 277 284
29. Aphase I clinical trial to determine the maximum tolerated dose and toxicity of IMOD in HIV infected asymptomatic patiets in Iran. Keirandish PMM, khorram Khorshid H, Heshmat R, Gharibdust F, Iranian J Allergy,Asthma Immunol 2007 6 5
30. Examination of Setarud (IMOD (TM)) in the management of patients with severe sepsis. Mahmoodpoor A, Eslami K, Mojtahedzadeh M, Najafi A, Ahmadi A, Dehnadi-Moghadam A, Mohammadirad A, Baeeri M, Abdollahi M, Daru-Journal of Faculty of Pharmacy 2010 18 23 28
31. The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Hicks P, Cooper DJ, Crit Care Resusc 2008 10 8 18304010
32. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL, Crit Care Med 2007 35 1244 1250 10.1097/01.CCM. 0000261890.41311.E9 17414736 (Pubitemid 46642649)
33. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Busund R, Koukline V, Utrobin U, Nedashkovsky E, Intensive care medicine 2002 28 1434 1439 10.1007/s00134-002-1410-7 12373468
34. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Critical care medicine 2003 31 2291 2301 10.1097/01.CCM.0000085089.88077.AF 14501959 (Pubitemid 37100831)
35. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial*. Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC, Critical care medicine 2004 32 2207 15640632
36. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. Wiedermann C, Kaneider N, BMC emergency medicine 2005 5 7 10.1186/1471-227X-5-7 16225672 (Pubitemid 41554965)
37. [Immunotherapy in complex treatment of surgical sepsis]. Reshetnikov EA, Baranov GA, Chuvanov MV, Skalozub O, Reshetnikov EA, Baranov GA, Chuvanov MV, Skalozub OI, Khirurgiia (Mosk) 2008 7 11 14
38. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. Li W, Ashok M, Li J, Yang H, Sama AE, Wang H, PLoS One 2007 2 1153 10.1371/journal.pone.0001153 17987129 (Pubitemid 351597638)
39. The green tea polyphenol epigallocatechin-3-gallate improves systemic hemodynamics and survival in rodent models of polymicrobial sepsis. Wheeler DS, Lahni PM, Hake PW, Denenberg AG, Wong HR, Snead C, Catravas JD, Zingarelli B, Shock 2007 28 353 359 10.1097/shk.0b013e3180485823 17545942 (Pubitemid 47282028)
40. In vivo and ex vivo immune response on herbal drug IMOD in animal experiments. Abedi-valugerdi MAN, Khorram Khorsid H, Tavasoti Kheiry M, Garibdust F, Iranian J Allergy Asthma Immunol 2007 6 9
41. Inhibition of tumor necrosis factor-alpha and nitrosative/oxidative stresses by Setarud (IMOD®); a molecular mechanism of protection against letrozole-induced polycystic ovary. Rezvanfar MA, Ahmadi A, Baeeri M, Abdollahi M, Toxicology Letters 2011 205 246
42. [The physiopathology of sepsis. Current concepts]. Bauer M, Anaesthesist 1996 45 312 322 10.1007/s001010050266 8702048 (Pubitemid 26151575)
43. Hemodynamic optimization of sepsis-induced tissue hypoperfusion. Cavazzoni SLZ, Dellinger RP, Critical Care 2006 10 2 17352796
44. Mitochondrial dysfunction, bioenergenic impairment, and metabolic down-regulation in sepsis. Levy R, shock 2007 28 24 28 10.1097/01.shk. 0000235089.30550.2d 17483747 (Pubitemid 46956458)
45. Preclinical and phase 1 clinical safety of Setarud (IMOD (TM)), a novel immunomodulator. Khairandish P, Mohraz M, Farzamfar B, Abdollahi M, Shahhosseiny MH, Madani H, Sadeghi B, Heshmat R, Gharibdoust F, Khorram-Khorshid HR, Daru-J Pharmaceut Sci 2009 17 148 156